Foghorn Therapeutics (FHTX) EBIT Margin (2020 - 2026)
Foghorn Therapeutics (FHTX) posted quarterly EBIT Margin of 660.33% for Q1 2026, down 27537.0% year-over-year from N/an in Q1 2025, and down 155.72% quarter-over-quarter from 258.22% in Q4 2025.
Powered by 
Analysis
Foghorn Therapeutics (FHTX) EBIT Margin (2020 - 2026) Analysis & Trends
Foghorn Therapeutics' EBIT Margin history runs 7 years deep, the most recent figure standing at 660.33% for Q1 2026.
- In Q1 2026, EBIT Margin fell 27537.0% year-over-year to 660.33%; the TTM figure through Mar 2026 stood at 301.34% (up 11307.0% YoY), while the FY2025 annual figure was 279.49%, up 17481.0% from the prior year.
- EBIT Margin for Q1 2026 stood at 660.33%, down from 258.22% in the prior quarter.
- The five-year high for EBIT Margin was 97.73% in Q3 2023, with the low at 840.51% in Q4 2024.
- The 5-year median for EBIT Margin is 441.29% (2023), against an average of 481.59%.
- The sharpest annual moves came in 2022 and 2024: EBIT Margin soared 6362525 bps in 2022, then tumbled 39922 bps in 2024.
- Foghorn Therapeutics' EBIT Margin stood at 762.09% in 2022, then jumped by 42 bps to 441.29% in 2023, then plunged by 90 bps to 840.51% in 2024, then surged by 69 bps to 258.22% in 2025, then sank by 156 bps to 660.33% in 2026.
- Business Quant data shows FHTX's EBIT Margin at 660.33% in Q1 2026, 258.22% in Q4 2025, and 226.92% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.92 Bn | 131.07 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.55 Bn | 77.56 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.55 Bn | 58.37 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.26 Bn | 53.13 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | - |
| 6 | BeOne Medicines | 39.98 Bn | 34.89 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.32 Bn | 32.01 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.42 Bn | 27.59 Bn | - | 19.75% |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn | -0.36% |
| 10 | Foghorn Therapeutics | 346.79 Mn | 278.71 Mn | - | -54.78% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -54.78% |
| Mar 31, 2026 | -660.33% |
| Dec 31, 2025 | -258.22% |
| Sep 30, 2025 | -226.92% |
| Jun 30, 2025 | -279.17% |
| Mar 31, 2025 | -384.96% |
| Dec 31, 2024 | -840.51% |
| Sep 30, 2024 | -305.48% |
| Jun 30, 2024 | -386.64% |
| Mar 31, 2024 | -558.30% |
| Dec 31, 2023 | -441.29% |
| Sep 30, 2023 | -97.73% |
| Jun 30, 2023 | -572.42% |
| Mar 31, 2023 | -627.56% |
| Dec 31, 2022 | -762.09% |
| Sep 30, 2022 | -425.97% |
| Jun 30, 2022 | -650.07% |
| Mar 31, 2022 | -709.29% |
| Dec 31, 2021 | -3,938.57% |
| Sep 30, 2021 | -64,051.22% |